Navigation Links
FDA Approves New Skin Cancer Drug First Tested in Arizona by Scottsdale Healthcare and TGen
Date:2/1/2012

umor growth in these patients with advanced skin cancer," said Daniel Von Hoff, MD, lead investigator. Dr. Von Hoff is physician-in-chief at TGen and chief scientific officer at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, where cancer patients receive treatment with promising new drugs.

"The drug works by inhibiting the Hedgehog pathway that is active in most basal cell cancers, preventing development, growth and survival of certain cancer cells. Results showed a durable clinical benefit – tumor shrinkage visible on X-ray or other physical exam or improvement in symptoms without tumor growth," said Glen Weiss, MD, director of Thoracic Oncology at Virginia G. Piper Cancer Center Clinical Trials and Clinical Associate Professor and Translational Physician Scientist at TGen.

Patient response during the clinical trials was assessed through physical examination and imaging. "Integrating genomic data with state-of-the-art clinical and imaging information to develop and apply targeted therapies has certainly taken a major step forward with the encouraging results from the Hedgehog trial," added Ron Korn, MD, a radiologist and medical director of the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

San Francisco-based Genentech developed Vismodegib. Successful results of early clinical trials at the Virginia G. Piper Cancer Center at Scottsdale Healthcare, Johns Hopkins University and Karmanos Cancer Institute were published in the Sept. 17, 2009 New England Journal of Medicine and led to interest in increased access to the drug.

"In some patients there is progression to life-threatening, locally advanced or metastatic tumors. Approved as a pill to be taken once a day, we believe this new drug represents an opportunity to improve quality of life for these patients," said Dr. Weiss.

Individuals seeking information about eligibility to participate in clinical trials at the Virginia G.
'/>"/>

SOURCE Scottsdale Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was ... in which he has overseen the company,s four facilities ... , and Costa Rica.  Mr. King joined Tegra ... sales, engineering and manufacturing experience in medical device businesses, ...
(Date:1/15/2014)... , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ... has fueled rapid growth of these markets. ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ... aspects in today,s growth in the pharmaceutical ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Nearly half a million patients in New York,s Hudson ... patient-centered medical homes, thanks to a Taconic Health Information ... six health plans to improve the quality of care ... Hudson Health Plan, MVP Health Care, UnitedHealthcare and Empire ...
... 8, 2011 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... development and commercialization of medically important pharmaceutical products for ... today announced its results for the fourth quarter and ... 31, 2010, the Company had cash, cash equivalents, interest ...
Cached Medicine Technology:Six Health Plans Pay $1.5 Million in Incentives to Create Medical Homes for Nearly Half a Million Hudson Valley Residents 2Six Health Plans Pay $1.5 Million in Incentives to Create Medical Homes for Nearly Half a Million Hudson Valley Residents 3Six Health Plans Pay $1.5 Million in Incentives to Create Medical Homes for Nearly Half a Million Hudson Valley Residents 4Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results 5
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... prostate cancer puts men at increased risk for diabetes ... published in the// Sept. 20 Journal of Clinical Oncology. ... survival rates, but they also have higher rates of ... Keating, MD, MPH, assistant professor of health care policy ...
... MedRP International, a medical staffing firm providing healthcare professionals ... into an agreement with// Kochi based InfoVision IELTS Training ... signed between the company's Asia-Pacific Operations, vice president Peter ... held at the Hotel Taj Residency here. ...
... a "no strings attached" $500,000 "genius" award from America's ... ,Gawande, 40, whose many articles and essays on medicine ... the most recognised of American writers, is one of ... the Foundation in Chicago Tuesday. ,Working across ...
... today that properly-funded preschools must be made available to ... start to good health and wellbeing throughout life. ... Starting Strong II report, released in Italy today, which ... the lowest spending on preschools and the worst-paid kindergarten ...
... that French people, particularly women are growing larger and fatter//. ... the French population aged above 15 years is affected by ... being obese.,Obesity is on a high in France, in spite ... This is reported by the study that is being conducted ...
... Maori are almost twice as likely to attempt suicide as ... generally than other New Zealanders. ,The survey conducted by ... on the prevalence of mental disorders among different ethnic groups ... people, including 2600 Maori. ,It was found that thirty ...
Cached Medicine News:Health News:Prostate Cancer Treatment Increases Risk of Diabetes and Heart Disease 2Health News:Indian American Surgeon Wins US "Genius" Award 2Health News:Make Preschool Available To All Kids - AMA 2Health News:Obesity on a high in France 2
... Bio-Rad isotopic anemia ... and minimal ,pipetting steps ... information about the processes ... and the benefit to ...
... The Zeus Scientific, Inc. ANA Screen ELISA test ... detect anti-nuclear antibodies (ANA) in human sera. When ... system is capable of detecting all ANAs commonly ... DNA (dsDNA), Jo-1, Sm, Sm/RNP, SSA, SSB, and ...
... Immuno Concepts manufactures slides that are ... technologist to decrease the number of pipetting ... patient sample dilutions on the slides. Ask ... procedure and these slides. These slide formats ...
... a patented HEp-2 cell line that has ... to SS-A/Ro autoantibodies, without affecting the other ... been published worldwide on the HEp-2000 ANA ... autoantibodies when used in place of standard ...
Medicine Products: